Title : Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes.

Pub. Date : 2021 Mar

PMID : 33747548






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Sodium-glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are second-line options after metformin, while cardiovascular outcome trials have been conducted to establish the cardiovascular safety of these antidiabetic drug classes. Metformin solute carrier family 5 member 2 Homo sapiens